Cadrenal Therapeutics Inc. will attend the BIO International Convention 2025, which takes place from June 16-19 in Boston. The company's executive leadership team will engage in one-on-one meetings with investors and potential partners to discuss the strategic direction and clinical development of its lead asset, tecarfarin.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604626958) on June 04, 2025, and is solely responsible for the information contained therein.